TNGX News and Press, Tango Therapeutics Inc.

2024-06-25 02:06:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

2024-06-15 03:00:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

Tango Therapeutics, Inc. (NASDAQ: TNGX), a clinical-stage biotechnology company committed to discovering and delivering the next generation of precision cancer medicines, today announced that Barbara Weber, M.D., President and Chief Executive Officer of Tango Therapeutics, is scheduled to present...

Medivir´s licensee, Tango Therapeutics, has discontinued development of its TNG348 clinical program PR Newswire STOCKHOLM , May 23, 2024 /PRNewswire/ -- Medivir AB (Nasdaq Stockholm: MVIR), a pharmaceutical company focused on developing innovative treatmen...

2024-05-23 07:17:41 ET More on Tango Therapeutics Seeking Alpha’s Quant Rating on Tango Therapeutics Historical earnings data for Tango Therapeutics Read the full article on Seeking Alpha For further details see: Tango Therapeutics to discontinue d...

– The phase 1/2 clinical trial of TNG348, a USP1 inhibitor, is being terminated due to toxicity observed in the initial study cohorts – – Cash runway extended into 2027, PRMT5 and CoREST clinical programs remain on track – Tango Therapeutics, Inc. (NA...

2024-05-08 13:53:49 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips Tango Therapeutics (NASDAQ: TNGX ) just reported results for the first quarter of 2024. Tango Therapeutics reported earnings per share of -35 cents. This was below the ana...

2024-05-08 09:52:13 ET More on Tango Therapeutics Seeking Alpha’s Quant Rating on Tango Therapeutics Historical earnings data for Tango Therapeutics Financial information for Tango Therapeutics Read the full article on Seeking Alpha For further...

– Dose expansion initiated in TNG908 phase 1/2 clinical trial – – Dose expansion expected to initiate in TNG462 phase 1/2 clinical trial in 2Q 2024 – – Clinical data expected in 2H 2024 from PRMT5 program – – Dose escalation...

2024-03-19 17:37:35 ET Gainers: Taysha Gene Therapies ( TSHA ) +32% . Canopy Growth Corporation ( CGC ) +14% . Sarcos Technology and Robotics ( STRC ) +12% . Adicet  ( ACET ) +6% . Bridger Aerospace Group Holdings ( BAER ) +4%...